Category: 16296-68-7

On May 9, 2019, Kurz, Guido; Camacho Gomez, Juan published a patent.Synthetic Route of 16296-68-7 The title of the patent was Preparation of novel dihydropyridine derivatives as androgen receptor and glucocorticoid receptor modulators. And the patent contained the following:

The present invention relates to novel dihydropyridine derivatives I [R1 = CN, C(O)NH2, COR5, CO2R5 (wherein R5 = (un)substituted alkyl, cycloalkyl); R2 = CN, COR8, CO2R8, SOnR8, C(O)NR8R9 (n = 1-2; R8 and R9 = (independently) H, (un)substituted alkyl, H, etc.; or R8 and R9 together with the nitrogen atom to which they are attached form (un)substituted 5-6 membered heterocycle which optionally comprises 1 heteroatom selected from O and N); R3 = H, NH2, CN, etc.; R4 = H, CN, (un)substituted alkyl, etc.; X1-X5 = (independently) CB1, N and CH (B1 = halo, CN, (un)substituted 5-6 membered heteroaryl, etc.)] and pharmaceutically acceptable salts thereof, as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathol. conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing’s syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism. Over three-hundred compounds I were prepared For example, heating a mixture of 3-(benzo[b]thiophen-3-ylmethylene)pentane-2,4-dione, Me 3-oxobutanoate and 30% aqueous ammonium in iso-PrOH at reflux temperature for 12 h afforded 25% II (both enantiomers were separated). Exemplified compounds I were evaluated for their androgen receptor and glucocorticoid receptor modulatory activities (data given for representative compounds I). The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Synthetic Route of 16296-68-7

The Article related to pyridine dihydropyridine preparation nuclear androgen glucocorticoid receptor modulator antitumor, benign prostate hyperplasia polycystic ovary syndrome treatment dihydropyridine preparation, hair loss hirsutism acne hypogonadism treatment dihydropyridine pyridine preparation and other aspects.Synthetic Route of 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On September 5, 1984, Ward, Robert William; Smith, Stephen Allan; Markwell, Roger Edward published a patent.Related Products of 16296-68-7 The title of the patent was Benzofuran- and benzothiophenecarboxylic acid derivatives. And the patent contained the following:

The title compounds I [X = O, S, SO, SO2, X1 = CH2; X = CH2, X1 = O; R = Ph, alkylphenyl, alkoxyphenyl, CF3C6H4, BrC6H4, ClC6H4, FC6H4, pyrrolyl, N-alkylpyrrolyl, furyl, thienyl, (un)substituted by Me, Cl, or Br; R1,R3 = H, alkyl; R2 = H, F, Cl, Br; R4 = H, alkyl] were prepared Thus, II (R2 = Br, R4 = R5 = H) was prepared by ring contraction of 6-bromo-4-chromanone with Tl(NO3)3, esterified, and subjected to Friedel-Crafts acylation with BzCl to give II (R2 = Br, R4 = Et, R5 = Bz) which was debrominated and saponified to II (R2 = R4 = H, R5 = Bz, III). At 5 mg/kg orally the phenylquinone writhing test in mice III gave analgesia in 90% of the animals. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Related Products of 16296-68-7

The Article related to benzofurancarboxylate preparation analgesic, benzothiophenecarboxylate, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenothiophenes and other aspects.Related Products of 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On June 15, 2011, Capek, Petr; Zhang, Yan; Barlow, Deborah J.; Houseknecht, Karen L.; Smith, Garry R.; Dickerson, Tobin J. published an article.Recommanded Product: 16296-68-7 The title of the article was Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors through Rational Design. And the article contained the following:

Botulinum neurotoxin (BoNT), the etiol. agent that causes the neuroparalytic disease botulism, has become a highly studied drug target in light of the potential abuse of this toxin as a weapon of bioterrorism. In particular, small mol. inhibitors of the light chain metalloprotease of BoNT serotype A have received significant attention and a number of small mol. and biol. inhibitors have been reported. However, all small mols. reported have been identified from either primary screens or medicinal chem. follow-up studies, and the pharmacokinetic profiles of these compounds have not been addressed. In this study, we have removed the pharmacol. liabilities of one of the best compounds reported to date, 2,4-dichlorocinnamate hydroxamic acid, and in the process uncovered a related class of benzothiophene hydroxamic acids that are significantly more potent inhibitors of the BoNT/A light chain, while also possessing greatly improved ADME properties, with the best compound showing the most potent inhibition of BoNT/A light chain reported (Ki = 77 nM). Using a strategy of incorporating traditional drug development filters early into the discovery process, potential liabilities in BoNT/A lead compounds have been illuminated and removed, clearing the path for advancement into further pharmacol. optimization and in vivo efficacy testing. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Recommanded Product: 16296-68-7

The Article related to botulinum neurotoxin serotype a protease inhibitor chlorocinnamate benzothiophene hydroxamate, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenothiophenes and other aspects.Recommanded Product: 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On September 12, 2013, Zhong, Zhaojin; Li, Zhuorong; Zhang, Dajun; Li, Yuhuan; Wang, Zhen; Gao, Rongmei; Shen, Jiajia published a patent.SDS of cas: 16296-68-7 The title of the patent was Preparation of phenyl oxazole derivatives as inosine monophosphate dehydrogenase inhibitors. And the patent contained the following:

Disclosed are Ph oxazolyl derivatives I [wherein R1 = H, halo, OH, alkyl, or alkoxy; R2 = absence, H, (un)substituted alkyl, CO2H, or sulfonyl; R = H, CN, (un)substituted alkyl, alkoxy, or aryloxy, etc.; p = 0-1; m = 0-3; n = 0-6] as an inosine monophosphate dehydrogenase (IMPDH) inhibitors for treating viral infection, neoplasm, and immune disease. For example, 3-methoxy-4-(oxazole-5-yl)aniline was reacted with 5-chloro-2-thiophenecarboxaldehyde to give II in 96.9% yield. In biol. test, II at 10 μg/mL showed 74.9% inhibition against IMPDH. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).SDS of cas: 16296-68-7

The Article related to preparation oxazole inosine monophosphate dehydrogenase inhibitor impdh human, treatment viral infection neoplasm immune disease, Heterocyclic Compounds (More Than One Hetero Atom): Oxazoles, Isoxazoles and other aspects.SDS of cas: 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On January 9, 2003, Basarab, Gregory; Eyermann, Joseph; Gowravaram, Madhusudhan; Green, Oluyinka; MacPherson, Lawrence; Morningstar, Marshall; Nguyen, Thanh published a patent.SDS of cas: 16296-68-7 The title of the patent was Preparation of pyrazolo[3,4-d]pyrimidines for inhibiting H. pylori infections. And the patent contained the following:

Title compounds I [wherein R1 and R2 = independently H, NH2, or (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl, alkoxy, or heterocyclyl; R3 = (un)substituted monocyclic or bicyclic ring system comprising 0-3 heteroatoms independently selected from N, O, or S; R4 = (un)substituted alkyl or (di)alkylamino, with exceptions; Y = CH2, CHCH3, SO, or SO2; and pharmaceutically acceptable salts thereof] were prepared For example, 6-hydrazino-1-isobutyl-3-methylpyrimidine-2,4-(1H,3H)-dione (4-step preparation given) was condensed with 1-naphthaldehyde in MeOH to give the hydrazone. Cyclocondensation with N-(4-formylphenyl)acetamide in DMF afforded II. Compounds of the invention exhibited glutamate racemase (MurI) activity with IC50 values of < 400 μM. Thus, I and pharmaceutical compositions containing them are useful in the treatment or prophylaxis of Helicobacter pylori (H. pylori) infection (no data). The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).SDS of cas: 16296-68-7

The Article related to pyrazolopyrimidine preparation antibacterial helicobacter pylori, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On June 16, 2016, Jones, Michael L.; Lilly, John C.; Ankala, Sudha V.; Singleton, Scott F. published a patent.Formula: C9H5ClOS The title of the patent was Preparation of quinazolinones, indazoles and other heterocyclic compounds as SOS inhibitors and antibiotic potentiators. And the patent contained the following:

The invention relates to preparation of quinazolinones of formula I, indazoles of formula II , wherein all the variables are as defined in the disclosure, and other heterocyclic compounds as SOS inhibitors and their use as antibiotics and as antibiotic potentiators. The example compound III was prepared by multistep synthesis according to the procedure shown and was tested for its antibacterial and SOS response-inhibiting activity (data disclosed). The compounds may act as colistin potentiators and SOS inhibitors. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Formula: C9H5ClOS

The Article related to quinazolinone indazole preparation sos inhibitor antibiotic potentiator combination chemotherapy, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Formula: C9H5ClOS

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On November 30, 2010, Hanna-Elias, Amir; Manallack, David T.; Levit, Alla; Nguyen, William; Ayad, Fadi; Perera, Glen; Shapiro, Marina; Irving, Helen R.; Coupar, Ian M.; Iskander, Magdy N. published an article.Related Products of 16296-68-7 The title of the article was Synthesis, testing and structure-activity studies on a library of 5-HT4 ligands. And the article contained the following:

Several indole derivatives and analogs comprising a range of related structural classes were designed, synthesized and tested as ligands for the 5-HT4 receptor. Within each series, binding experiments showed compounds with good affinity demonstrating high percentage displacement values at 1 μM. The most potent of these (I) had a pKi of 8.54 demonstrating very good affinity. These indole analogs were combined with 55 ligands that were previously produced to explore the structure-activity relationships of these 5-HT4 ligands. A CoMFA (Comparative Mol. Field Anal.) anal. was used to extend an earlier simple pharmacophore to suggest two new mol. features beyond the primary amino binding site. The pharmacophore confirmed that a newly described tetrahydroquinoline analog was able to match the basic requirements of the model and the pharmacol. of this mol. is provided in more detail. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Related Products of 16296-68-7

The Article related to indole derivative preparation 5ht4 ligand structure activity relationship pharmacophore, comparative mol field analysis indole derivative serotonin receptor binding, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Related Products of 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Li, Yitao; Yao, Wenqiang; Lin, Jian; Li, Falin; Wu, Yang; Xu, Junxing published an article in 2019, the title of the article was Design, Synthesis and Biological Activity of Novel Triazole Sulfonamide Derivatives Containing a Benzylamine Moiety.Synthetic Route of 16296-68-7 And the article contains the following content:

The 1,2,4-triazole-1,3-disulfonamide derivatives I [Ar = 2-thienyl, 2-pyrrolyl, 3-pyridyl, etc.] were synthesized via coupling of amines with triazole sulfonamide groups and evaluated for their fungicidal activity against cucumber downy mildew (CDM). Most of these derivatives exhibited better fungicidal activities than that of the com. cyanosole using bioassays. In particular, compounds I [Ar = 4-bromo-2-thiazolyl, 5-chloro-2-thienyl] showed the best fungicidal activity against CDM (EC50 = 6.91 and 10.62 mg/L). Comparative experiments demonstrated that the fungicidal activity of I [Ar = 4-bromo-2-thiazolyl, 5-chloro-2-thienyl] was better than the com. pesticides amisulbrom and cyanosole. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Synthetic Route of 16296-68-7

The Article related to triazole disulfonamide benzylamine preparation fungicidal, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Synthetic Route of 16296-68-7

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On January 28, 2021, Cuthbertson, Alan; Boehnke, Niels published a patent.Formula: C9H5ClOS The title of the patent was Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer. And the patent contained the following:

The invention is related to the preparation of compounds I [n = 1-3; R1-4 = OH or Q; Q = a tissue-targeting moiety selected from the group consisting of poly- and oligopeptides, proteins, DNA and RNA fragments, aptamers polyclonal or monoclonal antibodies, and a mixture of proteins or fragments or constructs of protein] their stereoisomers, hydrates, solvates and salts, and targeted radiopharmaceuticals, pharmaceutical compositions and combinations comprising them and their use for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients. The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Formula: C9H5ClOS

The Article related to peptide chelator conjugate preparation antitumor prostate cancer, preparation peptide chelator thorium 227 her2 fap psma conjugate, prostate specific membrane antigen carboxy hopo thorium 227 conjugate, targeted radiopharmaceutical prostate cancer and other aspects.Formula: C9H5ClOS

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

On May 8, 2019, Kurz, Guido; Camacho Gomez, Juan published a patent.Application In Synthesis of 5-Chlorobenzo[b]thiophene-3-carbaldehyde The title of the patent was Preparation of novel dihydropyridine derivatives as androgen receptor and glucocorticoid receptor modulators. And the patent contained the following:

The present invention relates to novel dihydropyridine derivatives I [R1 = CN, CHO, COR5, CO2R5 (wherein R5 = (un)substituted alkyl, cycloalkyl); R2 = CN, COR8, CO2R8, SOnR8, C(O)NR8R9 (n = 1-2; R8 and R9 = (independently) H, (un)substituted alkyl, cycloalkyl, etc.; or R8 and R9 together with the nitrogen atom to which they are attached form (un)substituted 5-6 membered heterocycle which optionally comprises 1 heteroatom selected from O and N); R3 = H, NH2, CN, etc.; R4 = H, CN, (un)substituted alkyl, etc.; or R1 and R3 or R2 and R4 form together (CR10R11)n (n = 3-4 wherein 1, 2 or 3 of CR10R11 moieties may be independently replaced by a group selected from O, S, C(O) and (un)substituted NH; R10, R11 = (independently) H, (un)substituted Ph or 5-6 membered heteroaryl, etc.); X1-X5 = (independently) CB1, N and CH (B1 = halo, CN, (un)substituted 5-6 membered heteroaryl, etc.)] and pharmaceutically acceptable salts thereof, as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathol. conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing’s syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism. Over two-hundred-seventy compounds I were prepared For example, heating a mixture of 3-(benzo[b]thiophen-3-ylmethylene)pentane-2,4-dione, Me 3-oxobutanoate and 30% aqueous ammonium in iso-PrOH at reflux temperature for 12 h afforded 25% II (both enantiomers were separated). Exemplified compounds I were evaluated for their androgen receptor and glucocorticoid receptor modulatory activities (data given for representative compounds I). The experimental process involved the reaction of 5-Chlorobenzo[b]thiophene-3-carbaldehyde(cas: 16296-68-7).Application In Synthesis of 5-Chlorobenzo[b]thiophene-3-carbaldehyde

The Article related to pyridine dihydropyridine preparation nuclear androgen glucocorticoid receptor modulator antitumor, benign prostate hyperplasia polycystic ovary syndrome treatment dihydropyridine preparation, hair loss hirsutism acne hypogonadism treatment dihydropyridine pyridine preparation and other aspects.Application In Synthesis of 5-Chlorobenzo[b]thiophene-3-carbaldehyde

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem